The case for patient-specific dosimetry in targeted radionuclide therapy is not primarily a clinical argument. It is a statistical argument. Once you accept the empirical data on inter-patient pharmacokinetic variability, the conclusion that population-average activity prescriptions will systematically misplace a large fraction of patients in the dose-response landscape follows from the arithmetic. This post works through that argument.
Three Independent Sources of Dose Variance
The absorbed dose deposited in any target tissue by a radiopharmaceutical is determined by three factors: the amount of radiotracer taken up by the tissue, the rate at which it clears, and the radiation sensitivity of the tissue to the dose it receives. In targeted radionuclide therapy, all three of these factors vary substantially across patients.
Tumor uptake is the most visible source of variance. Pre-treatment Ga-68 PET imaging for PSMA-targeted PRRT selection routinely shows that PSMA SUVmax varies by more than tenfold across patients who nominally meet the same eligibility criteria. That SUVmax variation is a proxy for receptor expression density and accessible binding sites, both of which determine how much therapeutic radionuclide the tumor tissue will accumulate. A tumor with SUVmax 25 on pre-treatment PET and a tumor with SUVmax 6 will not receive the same absorbed dose per unit of administered activity. The ratio of post-treatment absorbed doses will roughly track the pre-treatment uptake ratio, adjusted for differential retention kinetics.
Clearance half-life varies independently of uptake. Two patients with identical pre-treatment PET tracer avidity may have substantially different post-treatment retention kinetics for the therapeutic radiopharmaceutical. Clearance from tumor tissue depends on tracer washout rate (governed by receptor internalization, lysosomal processing, and physical dissociation), physical decay of the radionuclide, and the effective tissue residence time combining both processes. Published effective half-life data for Lu-177 in tumor lesions typically shows a range of 30 to 100 hours across patients, even in populations with comparable uptake. The cumulated activity, which is the product of peak activity and effective residence time, varies at least as much as uptake alone.
Organ radiosensitivity is a third independent variable that is less often discussed in the dosimetry literature but clinically consequential. Pre-existing renal compromise, prior cytotoxic chemotherapy, prior abdominal radiotherapy, and patient age all modulate how much absorbed dose a given kidney can tolerate before functional injury occurs. Two patients with measured kidney absorbed doses of 20 Gy will not necessarily have the same probability of nephrotoxicity if one has normal baseline renal function and one has CKD stage 2.
The Compound Variance Problem
Here is where the statistical argument becomes decisive. If uptake, clearance, and organ sensitivity each contribute independent variance to the clinical dose-response relationship, the effective variance in therapeutic outcome for a fixed administered activity is the convolution of all three distributions. Even if each individual factor varied by only plus or minus 50% around its population mean (a conservative estimate), the convolution of three independent distributions with that variance produces a final absorbed dose distribution spanning more than a factor of eight from the 10th to the 90th percentile.
The therapeutic window for targeted radionuclide therapy (the range of tumor absorbed dose associated with meaningful response without unacceptable toxicity) is not that wide. For PRRT in NET, tumor doses below approximately 20 to 25 Gy per cycle appear to be associated with substantially reduced biological effect, while cumulative kidney doses above 23 Gy are associated with rising nephrotoxicity risk. The gap between sub-therapeutic tumor dose and excessive kidney dose, when measured in terms of administered GBq, is narrow enough that the compound inter-patient variance distributes a significant fraction of patients outside the therapeutic window on any fixed-activity protocol.
We are not saying that fixed-activity protocols never work, or that every patient treated on a fixed-activity protocol is harmed. A substantial fraction of patients, probably those near the population median for uptake and clearance, will receive doses that fall within an acceptable range. The statistical argument is that the fraction of patients who fall outside the therapeutic window on fixed-activity dosing is non-trivial, and that this fraction is reducible by dosimetry-guided prescribing.
What the Dosimetry Literature Shows
Published dosimetry data from PRRT centers reporting retrospective or prospective dosimetry alongside standard administration protocols consistently show the pattern predicted by the statistical argument. Inter-patient kidney dose per GBq administered shows coefficients of variation of 30 to 50% in most series. Tumor dose per GBq administered varies even more widely, with some series reporting 10th-to-90th percentile ratios exceeding a factor of five for hepatic metastases in NET patients.
More directly relevant to the treatment decision are the studies that correlated measured absorbed doses with clinical outcomes. The dose-response data for PRRT, while not yet mature enough to define precise dose-response curves for every indication, consistently shows that higher tumor absorbed dose is associated with better lesion response, and that kidney doses above the reference constraint are associated with higher rates of late renal events. These relationships, taken together, make the dosimetric rationale for individualized prescribing compelling even in the absence of a completed randomized trial.
The Counterargument Worth Taking Seriously
The most serious counterargument to dosimetry-guided prescribing is practical rather than theoretical. Implementing cycle-by-cycle dosimetry requires quantitative SPECT capability, calibration infrastructure, physicist time, and serial imaging logistics that many PRRT programs genuinely do not have in place. If dosimetry adoption requires clinics to build capabilities they currently lack, and if the population-average protocol produces adequate outcomes for most patients, then the system-level cost-benefit calculation may favor continued use of fixed-activity prescribing over a costly infrastructure build.
This is a real tension, and we do not dismiss it. The practical argument for fixed-activity dosing is strongest in settings where the patient population is selected so stringently for high baseline uptake that the variance in the treated population is narrowed, and where renal function monitoring provides a late-stage safety net. For programs treating patients with median-to-high somatostatin receptor expression, limited renal comorbidity, and access to good monitoring, the fixed-activity approach may be reasonable.
Where the argument weakens is in programs treating patients with moderate uptake, patients with compromised baseline renal function, or patients where the available therapeutic window is narrow because of prior treatment history. In those situations, the compound variance problem becomes clinically decisive rather than theoretically interesting.
What Dosimetry-Guided Prescribing Actually Changes
Dosimetry-guided prescribing does not necessarily mean higher administered activity for every patient. For a patient with very high tumor uptake and rapid clearance from the kidney, the dosimetry calculation may indicate that a standard 7.4 GBq administration will deliver both a therapeutic tumor dose and a safe kidney dose. For that patient, dosimetry confirms that the standard protocol is appropriate, which is useful information even if it does not change the prescription.
For a patient with low tumor uptake and very slow kidney clearance, dosimetry may indicate that a standard activity would approach the kidney constraint without delivering a therapeutic tumor dose. For that patient, the calculation argues for reconsidering the treatment plan: perhaps a dose fractionation change, a different radiopharmaceutical, or a frank discussion with the patient about the likelihood of benefit.
For a patient at the other extreme, with very high uptake and very slow tumor clearance with normal kidney sensitivity, dosimetry may indicate that the standard activity is actually under-prescribing, and that a higher activity could be delivered safely. That patient is being under-treated by the fixed-activity protocol, and dosimetry is the tool that makes that visible.
The statistical argument is that these three types of patients exist in non-trivial proportions in any reasonably sized PRRT program. Dosimetry is the instrument that distinguishes them. Without it, clinicians are treating the population average and hoping that each patient happens to be close to it.